Biotech Values

[ghmm]

PTCT:

NICE Recommends Translarna™ (ataluren) for the Treatment of Patients with Nonsense Mutation Duchenne Muscular Dystrophy in England

http://finance.yahoo.com/news/nice-recommends-translarna-ataluren-treatment-151600792.html

I wonder just how NICE (pun intended) a discount they got to get the recommendation. Still a surprise positive for PTC

PTC and NHS England are in the process of finalizing an MAA outlining financial and clinical details surrounding the use of Translarna, including a confidential financial arrangement. The MAA is expected to allow PTC to collect further data on the efficacy of Translarna for the treatment of nmDMD over a five-year period with NICE guidance to be reviewed again at the end of that period.